Molecular cancer therapeutics
Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.
Masahiko Sumii, Takeshi Masuda, Kiyofumi Shimoji, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takahiro Mimae, Taku Nakashima, Hiroshi Iwamoto, Yoshihiro Miyata, Hironobu Hamada, Morihito Okada, Toshio Miyata, Noboru Hattori
Published: 202510.1158/1535-7163.MCT-24-0890
Abstract
Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with non-small-cell lung cancer (NSCLC), but the cure rate remains low because tolerant persister cancer cells can survive within the tumor during ICI treatment. We have prev…
Preview only. Read the full abstract at the source